{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,30]],"date-time":"2025-08-30T16:33:10Z","timestamp":1756571590046},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2021,6,8]],"date-time":"2021-06-08T00:00:00Z","timestamp":1623110400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,6,8]],"date-time":"2021-06-08T00:00:00Z","timestamp":1623110400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Chin. J. Integr. Med."],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1007\/s11655-021-3446-y","type":"journal-article","created":{"date-parts":[[2021,6,8]],"date-time":"2021-06-08T16:03:17Z","timestamp":1623168197000},"page":"643-648","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Monoclonal Gammopathy of Renal Significance (MGRS): Prospects for Treatment in Integrated Chinese and Western Medicine"],"prefix":"10.1007","volume":"27","author":[{"given":"Jin-pu","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ya-ting","family":"Du","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shen","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiang-rong","family":"Rao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,6,8]]},"reference":[{"key":"3446_CR1","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1016\/0002-9343(78)90522-3","volume":"64","author":"RA Kyle","year":"1978","unstructured":"Kyle RA. Monoclonal gammopathy of undetermined significance. Natural history in 241 cases. Am J Med 1978;64:814\u2013826.","journal-title":"Am J Med"},{"key":"3446_CR2","doi-asserted-by":"publisher","first-page":"4292","DOI":"10.1182\/blood-2012-07-445304","volume":"120","author":"N Leung","year":"2012","unstructured":"Leung N, Bridoux F, Hutchison CA, Nasr SH, Cockwell P, Fermand JP, et al. Monoclonal gammopathy of renal significance: when MGUS is no longer undetermined or insignificant. Blood 2012;120:4292\u20134295.","journal-title":"Blood"},{"key":"3446_CR3","doi-asserted-by":"publisher","first-page":"3583","DOI":"10.1182\/blood-2013-05-495929","volume":"122","author":"JP Fermand","year":"2013","unstructured":"Fermand JP, Bridoux F, Kyle RA, Kastritis E, Weiss BM, Cook MA, et al. How I treat monoclonal gammopathy of renal significance (MGRS). Blood 2013;122:3583\u20133590.","journal-title":"Blood"},{"key":"3446_CR4","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1038\/ki.2014.408","volume":"87","author":"F Bridoux","year":"2015","unstructured":"Bridoux F, Leung N, Hutchison CA, Touchard G, Sethi S, Fermand JP, et al. Diagnosis of monoclonal gammopathy of renal significance. Kidney Int 2015;87:698\u2013711.","journal-title":"Kidney Int"},{"key":"3446_CR5","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41581-018-0077-4","volume":"15","author":"N Leung","year":"2019","unstructured":"Leung N, Bridoux F, Batuman V, Chaidos A, Cockwell P, D\u2019Agati VD, et al. Publisher correction: The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group. Nat Rev Nephrol 2019;15:45\u201359.","journal-title":"Nat Rev Nephrol"},{"key":"3446_CR6","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1007\/s11255-017-1594-y","volume":"49","author":"M Ciocchini","year":"2017","unstructured":"Ciocchini M, Arbelbide J, Musso CG. Monoclonal gammopathy of renal signifcance (MGRS): the characteristics and significance of a new meta-entity. Int Urol Nephrol 2017;49:2171\u20132175.","journal-title":"Int Urol Nephrol"},{"key":"3446_CR7","doi-asserted-by":"publisher","first-page":"2344","DOI":"10.18632\/oncotarget.23412","volume":"9","author":"N Steiner","year":"2018","unstructured":"Steiner N, G\u00f6bel G, Suchecki P, Prokop W, Neuwirt H, Gunsilius E. Monoclonal gammopathy of renal significance (MGRS) increases the risk for progression to multiple myeloma: an observational study of 2935 MGUS patients. Oncotarget 2018;9:2344\u20132356.","journal-title":"Oncotarget"},{"key":"3446_CR8","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1111\/bjh.15987","volume":"186","author":"A Khera","year":"2019","unstructured":"Khera A, Panitsas F, Djebbari F, Kimberger K, Stern S, Quinn J, et al. Long term outcomes in monoclonal gammopathy of renal significance. Br J Haematol 2019;186:706\u2013716.","journal-title":"Br J Haematol"},{"key":"3446_CR9","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1111\/nep.13685","volume":"25","author":"C Pe\u00f1a","year":"2020","unstructured":"Pe\u00f1a C, Schutz NP, Riva E, Valjalo R, Majlis A, L\u00f3pez-Vidal H, et al. Epidemiological and clinical characteristics and outcome of monoclonal gammopathy of renal significance (MGRS)-related lesions in Latin America. Nephrology (Carlton) 2020;25:442\u2013449.","journal-title":"Nephrology (Carlton)"},{"key":"3446_CR10","doi-asserted-by":"publisher","first-page":"2409","DOI":"10.1182\/bloodadvances.2019031914","volume":"3","author":"A Jain","year":"2019","unstructured":"Jain A, Haynes R, Kothari J, Khera A, Soares M, Ramasamy K. Pathophysiology and management of monoclonal gammopathy of renal significance. Blood Adv 2019;3:2409\u20132423.","journal-title":"Blood Adv"},{"key":"3446_CR11","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.5858\/arpa.2013-0493-OA","volume":"138","author":"GA Herrera","year":"2014","unstructured":"Herrera GA. Proximal tubulopathies associated with monoclonal light chains: the spectrum of clinicopathologic manifestations and molecular pathogenesis. Arch Pathol Lab Med 2014;138:1365\u20131380.","journal-title":"Arch Pathol Lab Med"},{"key":"3446_CR12","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1016\/j.kint.2016.10.043","volume":"91","author":"M Lin","year":"2017","unstructured":"Lin M, Haas M. Paraprotein-associated thrombotic microangiopathy: expanding the spectrum of renal disease related to plasma cell dyscrasias. Kidney Int 2017;91:532\u2013534.","journal-title":"Kidney Int"},{"key":"3446_CR13","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1002\/ajh.24802","volume":"92","author":"A Dispenzieri","year":"2017","unstructured":"Dispenzieri A. POEMS syndrome: 2017 update on diagnosis, risk stratification, and management. Am J Hematol 2017;92:814\u2013829.","journal-title":"Am J Hematol"},{"key":"3446_CR14","doi-asserted-by":"publisher","first-page":"2400","DOI":"10.1681\/ASN.2020010054","volume":"31","author":"N Klomjit","year":"2020","unstructured":"Klomjit N, Leung N, Fervenza F, Sethi S, Zand L. Rate and predictors of finding monoclonal gammopathy of renal significance (MGRS) lesions on kidney biopsy in patients with monoclonal gammopathy. J Am Soc Nephrol 2020;31:2400\u20132411.","journal-title":"J Am Soc Nephrol"},{"key":"3446_CR15","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/j.mayocp.2015.01.024","volume":"90","author":"G Bhutani","year":"2015","unstructured":"Bhutani G, Nasr SH, Said SM, Sethi S, Fervenza FC, Morice WG, et al. Hematologic characteristics of proliferative glomerulonephritides with nonorganized monoclonal immunoglobulin deposits. Mayo Clin Proc 2015;90:587\u2013596.","journal-title":"Mayo Clin Proc"},{"key":"3446_CR16","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1681\/ASN.2017121319","volume":"29","author":"S Sethi","year":"2018","unstructured":"Sethi S, Rajkumar SV, D\u2019Agati VD. The complexity and heterogeneity of monoclonal immunoglobulin-associated renal diseases. J Am Soc Nephrol 2018;29:1810\u20131823.","journal-title":"J Am Soc Nephrol"},{"key":"3446_CR17","doi-asserted-by":"publisher","first-page":"2805","DOI":"10.1182\/blood-2015-07-658872","volume":"126","author":"RH Sayed","year":"2015","unstructured":"Sayed RH, Wechalekar AD, Gilbertson JA, Bass P, Mahmood S, Sachchithanantham S, et al. Natural history and outcome of light chain deposition disease. Blood 2015;126:2805\u20132810.","journal-title":"Blood"},{"key":"3446_CR18","first-page":"243","volume":"77","author":"K Amaador","year":"2019","unstructured":"Amaador K, Peeters H, Minnema MC, Nguyen TQ, Dendooven A, Vos JMI, et al. Monoclonal gammopathy of renal significance (MGRS) histopathologic classification, diagnostic workup, and therapeutic options. Neth J Med 2019;77:243\u2013254.","journal-title":"Neth J Med"},{"key":"3446_CR19","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1007\/s40620-020-00723-2","volume":"33","author":"K van","year":"2020","unstructured":"van Kruijsdijk RCM, Abrahams AC, Nguyen TQ, Minnema MC, Jacobs JFM, Limper M. Clone-directed therapy for proliferative glomerulonephritis with monoclonal immunoglobulin depositions: is it always necessary? Two case reports and literature review. J Nephrol 2020;33:611\u2013617.","journal-title":"J Nephrol"},{"key":"3446_CR20","unstructured":"Miller AS, Chipman D, Morris G, Srinivas D. Daratumumab for severe refractory proliferative glomerulonephritis with monoclonal immune deposits (PGNMID). Abstract. Am J Transplant 2017;17(suppl 3)."},{"key":"3446_CR21","first-page":"126","volume":"27","author":"Y Ren","year":"2020","unstructured":"Ren Y, Li S, Zhang GH, Rao XR. Thoughts on TCM syndrome differentiation and treatment in monoclonal gammopathy of renal significance. Chin J Inf Tradit Chin Med (Chin) 2020;27:126\u2013129.","journal-title":"Chin J Inf Tradit Chin Med (Chin)"},{"key":"3446_CR22","doi-asserted-by":"publisher","first-page":"e22057","DOI":"10.1002\/jbt.22057","volume":"32","author":"Z Yin","year":"2018","unstructured":"Yin Z, Yang J, Ning R, Liu Y, Feng M, Gu C, et al. Signal pathways, diseases, and functions associated with the miR-19a\/92a cluster and the use of berberine to modulate the expression of this cluster in multiple myeloma cells. J Biochem Mol Toxicol 2018;32:e22057.","journal-title":"J Biochem Mol Toxicol"},{"key":"3446_CR23","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1016\/j.biopha.2018.09.024","volume":"109","author":"L Shi","year":"2019","unstructured":"Shi L, Wu Y, Lv DL, Feng L. Scutellarein selectively targets multiple myeloma cells by increasing mitochondrial superoxide production and activating intrinsic apoptosis pathway. Biomed Pharmacother 2019;109:2109\u20132118.","journal-title":"Biomed Pharmacother"},{"key":"3446_CR24","first-page":"1396","volume":"20","author":"JK Yang","year":"2016","unstructured":"Yang JK, Lv FS, Han L. Effects of astragalus polysaccharides on the proliferation of bone marrow mesenchymal stem cells from patients with multiple myeloma. Chin J Tissue Eng Res (Chin) 2016;20:1396\u20131401.","journal-title":"Chin J Tissue Eng Res (Chin)"}],"container-title":["Chinese Journal of Integrative Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11655-021-3446-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11655-021-3446-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11655-021-3446-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,23]],"date-time":"2021-09-23T09:26:37Z","timestamp":1632389197000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11655-021-3446-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,8]]},"references-count":24,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["3446"],"URL":"https:\/\/doi.org\/10.1007\/s11655-021-3446-y","relation":{},"ISSN":["1672-0415","1993-0402"],"issn-type":[{"value":"1672-0415","type":"print"},{"value":"1993-0402","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,8]]},"assertion":[{"value":"22 March 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}